Literature DB >> 29099283

Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.

Nora Fernandez-Jimenez1, Athena Sklias1, Szilvia Ecsedi1, Vincent Cahais1, Davide Degli-Esposti1, Antonin Jay1, Pierre Benoit Ancey1, Hae Dong Woo1, Hector Hernandez-Vargas1, Zdenko Herceg1.   

Abstract

Breast cancer (BC) encompasses heterogeneous pathologies with different subtypes exhibiting distinct molecular changes, including those related to DNA methylation. However, the role of these changes in mediating BC heterogeneity is poorly understood. Lowly methylated regions (LMRs), non-CpG island loci that usually contain transcription factor (TF) binding sites, have been suggested to act as regulatory elements that define cellular identity. In this study, we aimed to identify the key subtype-specific TFs that may lead to LMR generation and shape the BC methylome and transcription program. We initially used whole-genome bisulfite sequencing (WGBS) data available at The Cancer Genome Atlas (TCGA) portal to identify subtype-specific LMRs. Differentially methylated regions (DMRs) within the BC PAM50 subtype-specific LMRs were selected by comparing tumors and normal tissues in a larger TCGA cohort assessed by HumanMethylation450 BeadChip (450K) arrays and TF enrichment analyses were performed. To assess the impact of LMRs on gene expression, TCGA RNA sequencing data were downloaded and Pearson correlations between methylation levels of loci presenting subtype-specific TF motifs and expression of the nearest genes were calculated. WGBS methylome data revealed a large number of LMRs for each of the BC subtypes. Analysis of these LMRs in the 450K datasets available for a larger sample set identified 7,765, 5,657, and 19 differentially methylated positions (DMPs) between normal adjacent tissues and tumor tissues from basal, luminal, and HER2-enriched subtypes, respectively. Unsupervised clustering showed that the discriminatory power of the top DMPs was remarkably strong for basal BC. Interestingly, in this particular subtype, we found 4,409 differentially hypomethylated positions grouped into 1,185 DMRs with a strong enrichment for the early B-cell factor 1 (EBF1) motifs. The methylation levels of the DMRs containing EBF1 motifs showed a strong negative correlation with the expression of 719 nearby genes, including BTS2 and CD74, two oncogenes known to be specific for basal BC subtype and for poor outcome. This study identifies LMRs specific to the three main BC subtypes and reveals EBF1 as a potentially important regulator of BC subtype-specific methylation and gene expression program.

Entities:  

Keywords:  DNA methylome; EBF1; breast cancer subtypes; lowly methylated regions; transcription factor binding sites

Mesh:

Substances:

Year:  2017        PMID: 29099283      PMCID: PMC5788421          DOI: 10.1080/15592294.2017.1373919

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  35 in total

1.  DNA-binding factors shape the mouse methylome at distal regulatory regions.

Authors:  Michael B Stadler; Rabih Murr; Lukas Burger; Robert Ivanek; Florian Lienert; Anne Schöler; Erik van Nimwegen; Christiane Wirbelauer; Edward J Oakeley; Dimos Gaidatzis; Vijay K Tiwari; Dirk Schübeler
Journal:  Nature       Date:  2011-12-14       Impact factor: 49.962

2.  Evaluation of the Infinium Methylation 450K technology.

Authors:  Sarah Dedeurwaerder; Matthieu Defrance; Emilie Calonne; Hélène Denis; Christos Sotiriou; François Fuks
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

3.  Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing.

Authors:  Volker Hovestadt; David T W Jones; Simone Picelli; Wei Wang; Marcel Kool; Paul A Northcott; Marc Sultan; Katharina Stachurski; Marina Ryzhova; Hans-Jörg Warnatz; Meryem Ralser; Sonja Brun; Jens Bunt; Natalie Jäger; Kortine Kleinheinz; Serap Erkek; Ursula D Weber; Cynthia C Bartholomae; Christof von Kalle; Chris Lawerenz; Jürgen Eils; Jan Koster; Rogier Versteeg; Till Milde; Olaf Witt; Sabine Schmidt; Stephan Wolf; Torsten Pietsch; Stefan Rutkowski; Wolfram Scheurlen; Michael D Taylor; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; Arndt Borkhardt; Hans Lehrach; Robert J Wechsler-Reya; Roland Eils; Marie-Laure Yaspo; Pablo Landgraf; Andrey Korshunov; Marc Zapatka; Bernhard Radlwimmer; Stefan M Pfister; Peter Lichter
Journal:  Nature       Date:  2014-05-18       Impact factor: 49.962

4.  A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate.

Authors:  Yin C Lin; Suchit Jhunjhunwala; Christopher Benner; Sven Heinz; Eva Welinder; Robert Mansson; Mikael Sigvardsson; James Hagman; Celso A Espinoza; Janusz Dutkowski; Trey Ideker; Christopher K Glass; Cornelis Murre
Journal:  Nat Immunol       Date:  2010-06-13       Impact factor: 25.606

Review 5.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 7.  Pioneer transcription factors in cell reprogramming.

Authors:  Makiko Iwafuchi-Doi; Kenneth S Zaret
Journal:  Genes Dev       Date:  2014-12-15       Impact factor: 11.361

8.  Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells.

Authors:  Aejaz Sayeed; Gloria Luciani-Torres; Zhenhang Meng; James L Bennington; Dan H Moore; Shanaz H Dairkee
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

9.  A global DNA methylation and gene expression analysis of early human B-cell development reveals a demethylation signature and transcription factor network.

Authors:  Seung-Tae Lee; Yuanyuan Xiao; Marcus O Muench; Jianqiao Xiao; Marina E Fomin; John K Wiencke; Shichun Zheng; Xiaoqin Dou; Adam de Smith; Anand Chokkalingam; Patricia Buffler; Xiaomei Ma; Joseph L Wiemels
Journal:  Nucleic Acids Res       Date:  2012-10-16       Impact factor: 16.971

10.  Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.

Authors:  Paul Guilhamon; Malihe Eskandarpour; Dina Halai; Gareth A Wilson; Andrew Feber; Andrew E Teschendorff; Valenti Gomez; Alexander Hergovich; Roberto Tirabosco; M Fernanda Amary; Daniel Baumhoer; Gernot Jundt; Mark T Ross; Adrienne M Flanagan; Stephan Beck
Journal:  Nat Commun       Date:  2013       Impact factor: 17.694

View more
  5 in total

1.  Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.

Authors:  Manjie Xing; Wen Fong Ooi; Jing Tan; Aditi Qamra; Po-Hsien Lee; Zhimei Li; Chang Xu; Nisha Padmanabhan; Jing Quan Lim; Yu Amanda Guo; Xiaosai Yao; Mandoli Amit; Ley Moy Ng; Taotao Sheng; Jing Wang; Kie Kyon Huang; Chukwuemeka George Anene-Nzelu; Shamaine Wei Ting Ho; Mohana Ray; Lijia Ma; Gregorio Fazzi; Kevin Junliang Lim; Giovani Claresta Wijaya; Shenli Zhang; Tannistha Nandi; Tingdong Yan; Mei Mei Chang; Kakoli Das; Zul Fazreen Adam Isa; Jeanie Wu; Polly Suk Yean Poon; Yue Ning Lam; Joyce Suling Lin; Su Ting Tay; Ming Hui Lee; Angie Lay Keng Tan; Xuewen Ong; Kevin White; Steven George Rozen; Michael Beer; Roger Sik Yin Foo; Heike Irmgard Grabsch; Anders Jacobsen Skanderup; Shang Li; Bin Tean Teh; Patrick Tan
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression.

Authors:  Napat Armartmuntree; Apinya Jusakul; Chadamas Sakonsinsiri; Watcharin Loilome; Somchai Pinlaor; Piti Ungarreevittaya; Chern Han Yong; Anchalee Techasen; Kanokwan Imtawil; Ratthaphol Kraiklang; Nattawan Suwannakul; Waleeporn Kaewlert; Timpika Chaiprasert; Raynoo Thanan; Mariko Murata
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

3.  Epigenetic remodelling of enhancers in response to estrogen deprivation and re-stimulation.

Authors:  Athena Sklias; Andrea Halaburkova; Ludovica Vanzan; Nora Fernandez Jimenez; Cyrille Cuenin; Liacine Bouaoun; Vincent Cahais; Victor Ythier; Aurélie Sallé; Claire Renard; Geoffroy Durand; Florence Le Calvez-Kelm; Rita Khoueiry; Rabih Murr; Zdenko Herceg
Journal:  Nucleic Acids Res       Date:  2021-09-27       Impact factor: 16.971

4.  DNA methylation signatures of breast cancer in peripheral T-cells.

Authors:  Surabhi Parashar; David Cheishvili; Niaz Mahmood; Ani Arakelian; Imrana Tanvir; Haseeb Ahmed Khan; Richard Kremer; Catalin Mihalcioiu; Moshe Szyf; Shafaat A Rabbani
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

Review 5.  The Potential Equivalents of TET2 Mutations.

Authors:  Sergiu Pasca; Ancuta Jurj; Mihnea Zdrenghea; Ciprian Tomuleasa
Journal:  Cancers (Basel)       Date:  2021-03-24       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.